Search
NCX 1022
go.drugbank.com/drugs/DB05410ExperimentalNCX is an NO-releasing derivative of hydrocortisone.
Tinidazole
go.drugbank.com/drugs/DB00911ApprovedInvestigationalA nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.
Camazepam
go.drugbank.com/drugs/DB01489ExperimentalIllicitIn the United States camazepam is regulated as a Schedule IV controlled substance. … Similarly to other drugs in its class, it has antxiolytic, anticonvulsant, hypnotic, and skeletal muscle relaxant properties.
Mitoquinone
go.drugbank.com/drugs/DB05063InvestigationalMitochondrial dysfunction also has been shown to represent an early critical event in the pathogenesis of the sporadic form of Parkinson's disease. … In 2004, a genomic study of hereditary early-onset Parkinson's disease demonstrated a direct molecular link between mitochondrial dysfunction and the pathogenesis of Parkinson's disease.
GTX-758
go.drugbank.com/drugs/DB14969InvestigationalGTX-758 is under investigation in clinical trial NCT01420861 (GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer).
Flupirtine
go.drugbank.com/drugs/DB06623InvestigationalFlupirtine is a pyridine derivative that is in clinical use as a nonopioid analgesic. It was approved for the treatment of pain in 1984 in Europe. … It is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment of fibromyalgia.
TC-2216
go.drugbank.com/drugs/DB06044InvestigationalTC-2216 is an investigational novel small molecule that is being developed as an oral treatment for depression and anxiety disorders.
NOX-700
go.drugbank.com/drugs/DB05464ExperimentalNOX-700, an new orally active dithiocarbamate-based nitric oxide (NO) blocking agent that is in development for the treatment of diabetes mellitus (type 2 diabetes). … In animal studies, NOX-700 lowered serum glucose, improved glucose tolerance, and reduced the percentage of total glycated hemoglobin.
Mitumomab
go.drugbank.com/drugs/DB06462ExperimentalMitumomab, an anti-BEC-2 monoclonal antibody derived from mice, was previously studied to treat small cell lung carcinoma in combination with BCG vaccination.